Congress caps epinephrine costs at $60 for insured patients
H.R. 5139 — EPIPEN Act · Filed by Maxwell Frost (D-FL) · 1 cosponsor · Introduced Sep 4, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires health insurance plans to cover epinephrine delivery systems (EpiPens, nasal sprays, and similar devices) with no deductible and a maximum out-of-pocket cost of $60 per package of two devices. The requirement applies to group health plans, employer-sponsored insurance, and individual insurance policies. Plans may still charge higher costs for out-of-network providers.
Why we flagged it
The bill's operative mechanism is a price cap and deductible waiver for a specific essential medication class, designed to reduce out-of-pocket costs for patients with severe allergies. This is straightforward consumer protection legislation, not a hidden subsidy or regulatory carve-out.
What the text implies
- The $60 cap may incentivize insurers to negotiate lower wholesale prices with manufacturers, potentially reducing prices across the market beyond just the insured population.
- Out-of-network carve-out allows plans to charge higher costs for out-of-network epinephrine, which may disadvantage patients in rural areas or those without in-network access to these devices.
The full analysis lists 4 implications of this text.
Who stands to gain
patients with severe allergies (primary beneficiary); employers offering health plans (reduced employee out-of-pocket costs may improve retention and prod